血清HBV RNA水平预测抗HBV治疗效果的研究进展

摘要/Abstract

摘要： 在乙肝患者中,共价闭环DNA (cccDNA)持续存在于肝脏中,这是其导致慢性化的重要因素,且目前治疗药物(聚乙二醇)干扰素和核苷(酸)类似物(NA)均不能清除cccDNA。血清HBV RNA能反映共价闭合环DNA的转录活性及水平,因而其在反映治疗抗病毒方面、停药后病毒反弹预测方面有重要作用。本文综述了血清HBV RNA 水平预测抗HBV治疗效果的研究进展。

关键词: 血清HBV RNA, 乙型肝炎病毒, cccDNA, 抗病毒治疗

巩子菱, 邹志强. 血清HBV RNA水平预测抗HBV治疗效果的研究进展[J]. 肝脏, 2023, 28(2): 261-263.

[1] Yan H,Zhong G,Xu G,et al.Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.Elife,2012,1:e00049.
[2] Valery PC,Laversanne M,Clark PJ,et al.Projections of primary liver cancer to 2030 in 30 countries worldwide.Hepatology, 2018,67(2):600-611.
[3] 王贵强,王福生,庄辉,等.慢性乙型肝炎防治指南(2019年版).临床肝胆病杂志,2019,35(12):2648-2669.
[4] Nassal M.HBV cccDNA:viral persistence reservoir and key obstacle for a cure of chronic hepatitis B .Gut,2015,64(12):1972-1984.
[5] 鲁凤民,王杰,庄辉.HBV RNA病毒样颗粒的潜在临床意义.Hepatol Int,2016,32(9):1635-1636.
[6] Li W,Zhao J,Zou Z,et al.Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-nave patients with acute an chronic HBV infection .PLoS One,2014,9(2):e89046.
[7] 鲁凤民,窦晓光,张文宏,等. 慢性乙型肝炎患者血清HBV RNA检测的临床应用.临床肝胆病杂志,2018,34(5):934-938.
[8] Wang J,Shen T,Huang X,et al.Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.J Hepatol ,2016,65(4):700-710.
[9] Liu Y,Jiang M,Xue J,et al.Serum HBV RNA quantification:useful for monitoring natural historu of chronic hepatitis B infection.BMC Gastroenterol,2019,19(1):53.
[10] Giersch K,Allweiss L,Volz T,et al.Serum HBV pgRNA as a clinical marker for cccDNA activity.J Hepatol ,2017,66(2):460-462.
[11] Wang J,Shen T,Huang X,et al.Serum hepatitis B virus RNA is encapsidated pregenome RNA that maybe associated with persistence of viral infection and rebound.J Hepatol,2016,65(4):700-710.
[12] Wang X,Chi X,Wu R,et al.Serum HBV RNA correlated wirh intrahepatic cccDNA more strongly rhan other HBV markers during peg-interferon treatment. Virol J,2021,18(1):4.
[13] Luo H,Zhang XX,Cao LH,et al.Serum hepatitis B vitus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients.World J Gastroentero,2019,25(6):719-728.
[14] Huang YW,Takahashi S,Tsuge M,et al.On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.Antivir Ther,2014,20(4):369-375.
[15] Jia W,Zhu MQ,Qi X,et al.Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a.VirolJ,2019,16(1):61.
[16] Yu XQ,Wang MJ,Yu DM,et al.Comparison of serum hepatitis b virus rna levels and quasispecies evolution patterns between entecavir and pegylated-interferon monotreatment in chronic hepatitis B patients.J Clin Microbiol,2020,58(9):e00075-20.
[17] Jansen L,Kootstra NA ,Van Dort KA,et al.Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues.J Infect Dis,2016,213(2):224-232.
[18] Gao Y,Li Y,Meng Q,et al.Serum hepatitis B virus DNA,RNA,and HBsAg:which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment?.J Clin Microbiol,2017,55(10):2972-2982.
[19] Van campenhout M J H ,Van bommelf,Pfefferkorn M,et al.Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment.Hepatology,2018,68(3):839-847.
[20] Van Bommel F,Bartens A ,Mysickova A,et al.Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors.Hepatology,2015,61(1):66-76.
[21] Terrault NA,Lok ASF,McMahon BJ,et al.Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance.Hepatology,2018,67(4):1560-1599.
[22] Wang J,Shen T,Huang X,et al.Serum hepatitis B virus RNA is encapsidated pregenome RNA that maybe associated with persistence of viral infection and rebound.J Hepatol,2016,65(4):700-710.
[23] Wang J,Chen X,Wu Y,et al.Serum HBV RNA is a potential predictor of hepatitis B surface antigen reversion .J Hepatol,2018,2(10):1168-1171.
[24] Seto W K,Liu KS,Mak LY,et al.Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation.Gut,2021,70(4):775-783.
[25] LIU H.The curative effect of two drugs in the treatment of HBeAg positive chronic hepatitis B and the forecast factors analysis of the serological conversion.Int J Clin Exp Med,2017,16(9):883-886.
[26] Yang L,Shi LP,Chen HJ,et al.Isothiafludine,a novel nonnucleoside compound,inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation.Acta Pharmacol Sin,2014,35(3):410-418.
[27] Lam AM,Ren S,Espiritu C,et al.Hepatitis B virus capsid assembly modulators,but not nucleoside analogs,inhibit the production of extracellular pregenomic RNA and spliced RNA variants.Antimicrob Agents Ch,2017,61(8):e680-717.
[28] Pan JQ,Tong SM,Kang L,et al.New anti-hepatitis B virus drugs under development and evaluation.Curr Opin in Infect Dis,2016,29(6):632-638.

血清HBV RNA水平预测抗HBV治疗效果的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈静娜, 郝孟翰, 宋欣络, 王冰, 高攀, 钱宇妍, 陈岩松, 黄文俊, 赵萌, 张桠婕. 慢性乙型肝炎新的治疗方法[J]. 肝脏, 2023, 28(2): 135-145.
[2]	刘云霄, 符艳, 牛丽娜, 窦婧, 王晓忠. 核苷(酸)类似物治疗与乙型肝炎病毒相关肝癌术后生存的meta分析[J]. 肝脏, 2023, 28(2): 181-188.
[3]	方芷欣, 邓芮, 孙剑. 血清HBV RNA的基础与临床应用研究进展[J]. 肝脏, 2023, 28(1): 30-32.
[4]	陆伟, 张占卿, 阎俪, 黄丹, 林维佳, 周新兰, 丁荣蓉, 王雁冰, 李秀芬. 血清定量HBsAg和HBV DNA预测HBeAg阳性慢性HBV感染显著肝炎活动的性能比较[J]. 肝脏, 2023, 28(1): 86-94.
[5]	文夏杰, 鲁凤民, 贾继东. 慢性乙型肝炎治愈临床研究进展[J]. 肝脏, 2022, 27(9): 947-949.
[6]	李玉坤, 顾智强, 姜倩倩, 陈香梅, 鲁凤民. 整合的HBV DNA在慢性乙型肝炎患者病毒复制及慢性感染维持中的潜在作用[J]. 肝脏, 2022, 27(9): 953-955.
[7]	郑惠芳, 林升龙, 郑嵩, 黄雨欣, 肖珊颖, 叶子杰, 林明华, 高海兵. HBV相关慢加急性肝衰竭并发细菌感染的预测模型的构建[J]. 肝脏, 2022, 27(9): 966-972.
[8]	高政聪, 雷作汉, 郭舜琴. 低血红蛋白/红细胞分布宽度比值对HBV相关失代偿期肝硬化预后的评价[J]. 肝脏, 2022, 27(9): 1004-1007.
[9]	谢志伟, 陆霭琪, 杨可立, 陈彬彬, 关玉娟, 肖光明, 李剑萍. 乙型肝炎病毒相关慢加急性肝衰竭患者血清miRNA差异表达谱及其预后预测价值[J]. 肝脏, 2022, 27(8): 853-857.
[10]	张磊, 黄育红, 罗凌, 汪丽萍, 方春华, 冉斌, 李应. 长期抗病毒治疗的慢性乙型肝炎患者血清TIMP-1和M-CSF水平变化[J]. 肝脏, 2022, 27(8): 863-867.
[11]	谢巧华, 王巍, 唐龙, 陈佳霖, 苏妙芳, 蔡奇志. 急性肾损伤对失代偿期乙型肝炎肝硬化患者临床预后的影响[J]. 肝脏, 2022, 27(8): 868-870.
[12]	王利慧, 王荣希, 赵泽源, 郭振凯. 失代偿期乙型肝炎肝硬化患者门静脉血栓形成的临床意义[J]. 肝脏, 2022, 27(8): 874-876.
[13]	仲小强, 储旭东, 陈海燕, 高太俊. HBV相关慢加急性肝衰竭患者并发细菌感染影响因素及预后结局分析[J]. 肝脏, 2022, 27(7): 748-751.
[14]	张祎, 王舟, 杨斌. IL-17家族细胞因子与慢性乙型肝炎肠道菌群的相关性分析[J]. 肝脏, 2022, 27(7): 759-761.
[15]	阮鹏, 何春萍, 黄超, 周瑞. 改良Alu-PCR技术检测HepG2.2.15细胞HBV整合的研究[J]. 肝脏, 2022, 27(7): 785-788.